Inequalities in baseline patient reported outcomes at prostate cancer diagnosis in an Irish cohort
Abstract
Background: Pre-treatment assessment of patient-reported outcome measures (PROMs) in prostate cancer (PCa) patients provides context for treatment decisions and changes in urinary, bowel and sexual domains. Since 2025, the Irish Prostate Cancer Outcomes Research (IPCOR) has been collecting PROMs at diagnostic biopsy, facilitating linkage of sociodemographic factors with pre-treatment symptoms and diagnoses.
Methods: Descriptive analyses outline demographic and clinical characteristics. Baseline EPIC-26, EORTC QLQ-C30 and PR25 scores were compared by tumour positivity at biopsy, symptoms and treatment pathways. Unadjusted associations were examined using ANOVA and chi‑square tests. Multivariable linear regression models identified independent predictors of PROM variation.
Results: Baseline PROMs were available for 383 participants (68% tumour positive). Tumour‑positive men were significantly older (mean 65.5 vs 61.3 years; p < 0.001). In unadjusted analyses, income, occupation, education, smoking and ethnicity were associated with variation across multiple PROM domains. No statistically significant differences were reported between PCa and non-cancer groups or across treatment groups. Older age was associated with lower odds of surgical treatment (aOR 0.86, 95% CI 0.75-0.96). Greater comorbidity burden (e.g. EPIC-26 urinary irritative: β -3.6, 95% CI -5.78 to -1.03, p = 0.005) and older age (e.g. EORTC-QLQ-C30 diarrhoea symptoms: β -0.52, 95% CI -0.88 to -0.15, p = 0.006) were the main predictors of poorer baseline PROM scores. Socioeconomic variables demonstrated moderate associations after adjustment.
Conclusions: Baseline inequalities are evident at diagnosis: older age and comorbidity burden independently predict both poorer PROMs and higher tumour positivity. Baseline PROMs should be considered in patient-centred treatment decisions. These findings highlight the need for equity‑focused assessment and tailored support at diagnosis and treatment selection.
Key messages: • Irish PROMs data show that collecting baseline outcomes at diagnosis supports patient‑centred treatment decisions. This equity‑focused approach may inform prostate cancer care pathways across Europe.
• Inequalities in prostate cancer are apparent at diagnosis. Addressing them could improve equitable care in Ireland and may have relevance for broader European contexts.
Related
- Asymptomatic Appendiceal Metastasis From Prostate Cancer Mimicking Metastatic Lymph Node as Solitary Disease on PSMA PET/CT Scan: The First Reported Case of Presurgical Diagnosis and Review of Literature.
- Survival outcomes with Lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer patient according to baseline tumor characteristics.
- Association of baseline non-severe anemia with clinical outcomes following the first recorded diagnosis of systemic sclerosis: A matched cohort study.
- Baseline Patient and Tumour Characteristics Associated with Mental Health in Men Undergoing Active Surveillance for Prostate Cancer
- Baseline serum carcinoembryonic antigen (CEA) is an independent prognostic biomarker for metastatic castration-resistant prostate cancer (mCRPC) patients receiving 177Lu-PSMA therapy
BibTeX
@article{fennessy2026inequalities,
title = {{Inequalities in baseline patient reported outcomes at prostate cancer diagnosis in an Irish cohort}},
author = {S Fennessy and N Gordon and W Farooq and L Hoang and W Watson and P Fitzpatrick and D Galvin},
journal = {The European Journal of Public Health},
year = {2026},
month = oct,
doi = {10.1093/eurpub/ckag169.850},
url = {https://doi.org/10.1093/eurpub/ckag169.850},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Inequalities in baseline patient reported outcomes at prostate cancer diagnosis in an Irish cohort
AU - S Fennessy
AU - N Gordon
AU - W Farooq
AU - L Hoang
AU - W Watson
AU - P Fitzpatrick
AU - D Galvin
PY - 2026
DA - 2026/10/01
JO - The European Journal of Public Health
DO - 10.1093/eurpub/ckag169.850
UR - https://doi.org/10.1093/eurpub/ckag169.850
AB - Background: Pre-treatment assessment of patient-reported outcome measures (PROMs) in prostate cancer (PCa) patients provides context for treatment decisions and changes in urinary, bowel and sexual domains. Since 2025, the Irish Prostate Cancer Outcomes Research (IPCOR) has been collecting PROMs at diagnostic biopsy, facilitating linkage of sociodemographic factors with pre-treatment symptoms and diagnoses. Methods: Descriptive analyses outline demographic and clinical characteristics. Baseline EPIC-26, EORTC QLQ-C30 and PR25 scores were compared by tumour positivity at biopsy, symptoms and treatment pathways. Unadjusted associations were examined using ANOVA and chi‑square tests. Multivariable linear regression models identified independent predictors of PROM variation. Results: Baseline PROMs were available for 383 participants (68% tumour positive). Tumour‑positive men were significantly older (mean 65.5 vs 61.3 years; p < 0.001). In unadjusted analyses, income, occupation, education, smoking and ethnicity were associated with variation across multiple PROM domains. No statistically significant differences were reported between PCa and non-cancer groups or across treatment groups. Older age was associated with lower odds of surgical treatment (aOR 0.86, 95% CI 0.75-0.96). Greater comorbidity burden (e.g. EPIC-26 urinary irritative: β -3.6, 95% CI -5.78 to -1.03, p = 0.005) and older age (e.g. EORTC-QLQ-C30 diarrhoea symptoms: β -0.52, 95% CI -0.88 to -0.15, p = 0.006) were the main predictors of poorer baseline PROM scores. Socioeconomic variables demonstrated moderate associations after adjustment. Conclusions: Baseline inequalities are evident at diagnosis: older age and comorbidity burden independently predict both poorer PROMs and higher tumour positivity. Baseline PROMs should be considered in patient-centred treatment decisions. These findings highlight the need for equity‑focused assessment and tailored support at diagnosis and treatment selection. Key messages: • Irish PROMs data show that collecting baseline outcomes at diagnosis supports patient‑centred treatment decisions. This equity‑focused approach may inform prostate cancer care pathways across Europe. • Inequalities in prostate cancer are apparent at diagnosis. Addressing them could improve equitable care in Ireland and may have relevance for broader European contexts.
SN - 1101-1262
SN - 1464-360X
ER -